Empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, has demonstrated benefits in reducing cardiovascular events and mortality in T2D patients [10]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.